{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T21:13:30Z","timestamp":1770412410490,"version":"3.49.0"},"reference-count":22,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1586\/17474086.2013.831324","type":"journal-article","created":{"date-parts":[[2013,10,2]],"date-time":"2013-10-02T07:28:18Z","timestamp":1380698898000},"page":"543-546","source":"Crossref","is-referenced-by-count":0,"title":["The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia"],"prefix":"10.1586","volume":"6","author":[{"given":"Stefano","family":"Molica","sequence":"first","affiliation":[{"name":"Department Hematology-Oncology,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.8762"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2013.814845"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-423194"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-362624"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"issue":"15","key":"e_1_3_3_9_1","article-title":"Activity and tolerability of the Bruton\u2019s tyrosine kinase (BTK) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): interim results of a phase Ib\/II study","volume":"29","author":"Byrd J","year":"2011","unstructured":"Byrd J, Blum K, Burger J et al. Activity and tolerability of the Bruton\u2019s tyrosine kinase (BTK) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): interim results of a phase Ib\/II study. J. Clin. Oncol. 29(15), abstract 6508 (2011).","journal-title":"J. Clin. Oncol"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.655"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.0680"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-452607"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.3748"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1303054"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","unstructured":"Burger JA Keating MJ Wierda WG et al. The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients. Presented at: ASH Annual Meeting Atlanta GA USA 8\u201311 December 2012 (Abstracts 187).","DOI":"10.1182\/blood.V120.21.187.187"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","unstructured":"Jaglowski SM Jones JA Flynn JM et al. A phase Ib\/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and related diseases. Presented at: ASCO Annual Meeting 2012 Chicago IL USA 1\u20135 June 2012 (Abstracts 6508).","DOI":"10.1200\/jco.2012.30.15_suppl.6508"},{"key":"e_1_3_3_18_1","doi-asserted-by":"crossref","unstructured":"O'Brien SM Barrientos JC Flinn IW et al. Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)\/rituximab (R) (BR) in patients (pts) with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): Interim results of a Phase Ib\/II study. J. Clin. Oncol. 30(Suppl.) Abstract 6515 (2012).","DOI":"10.1200\/jco.2012.30.15_suppl.6515"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.8061"},{"key":"e_1_3_4_2_1","unstructured":"A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. CLINICALTRIALS.GOV IDENTIFIER: NCT01611090."},{"key":"e_1_3_4_3_1","unstructured":"A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE\u2122). CLINICALTRIALS.GOV IDENTIFIER: NCT01578707."},{"key":"e_1_3_4_4_1","unstructured":"A Multicenter Open-label Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE\u2122-2). CLINICALTRIALS.GOV IDENTIFIER: NCT01722487."},{"key":"e_1_3_4_5_1","unstructured":"A Multicenter Phase 2 Study of PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion. CLINICALTRIALS.GOV IDENTIFIER: NCT01744691."}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/17474086.2013.831324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:37:45Z","timestamp":1770374265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/17474086.2013.831324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1586\/17474086.2013.831324"],"URL":"https:\/\/doi.org\/10.1586\/17474086.2013.831324","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}